NEW YORK, Aug. 11, 2015 /PRNewswire/ -- At the just-completed annual gathering of clinical laboratory professionals, the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, companies rolled out new and advanced products for the substance abuse testing market. At a time when substance abuse testing can take place in a variety of settings – in hospitals, physician offices, criminal justice agencies, workplaces, rehabilitation centers, occupational health clinics, and homes – new products that can help ensure accurate results are in demand. Kalorama Information noted at the AACC meeting trends toward tighter specimen confirmation, point of care testing products, and improved laboratory screening in substance abuse testing. The market research publisher's report, Drugs of Abuse Testing Markets covers trends and markets in drugs of abuse testing. As part of its coverage, the report offers estimates and forecasts for drugs of abuse markets and market segment estimates by type of sample, by application, by region, and by provider.
Drugs of Abuse Testing Markets can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=87714&productid=8284197.
"In the past few years, there has been an increasing transition from instrumented screening for substance abuse to testing with disposable devices," said Bruce Carlson, Publisher of Kalorama Information. "Just about every major immunoassay company offers tests for the basic drugs of abuse."
OraSure Technologies' Intercept i2he features an oral fluid, non-invasive collection process that can be administered quickly virtually anytime or anywhere. The system enables accurate testing for drugs of abuse, including marijuana, cocaine, PCP, opiates, and amphetamines – including Ecstasy (all included on their standard panel). Intercept can also be used to screen for Barbiturates, Benzodiazepines and Methadone. Once FDA-approved, Intercept i2he oral fluid assays are designed to run on various clinical chemistry automated analyzers with the same efficiency as current fully automated urine based drug tests.
Sample integrity is one of the biggest issues in drug testing. Even under observation, sample adulteration and/or substitution is very common. Observed collections are invasive, inefficient, expensive, and require extensive organizational effort. In an effort to eliminate observed collections, false negative results and adulteration, Marker Test Diagnostics has introduced UR Code to the market. UR Code is an oral marker that internally "bar-codes" a subject's urine and eliminates the need to supervise urine collection. The goal of UR Code is to be an accurate, secure, and cost-effective solution that will make sample substitution impossible so that authorities can finally rely on truly accurate results.
Mindray's MedTest BS-480 Ensemble brings improved laboratory screening to mid-volume labs. The BS-480 Ensemble for chemistry testing and urine drugs of abuse screening has a broad and expanding menu of 29 barcoded chemistry reagents, 3 electrolytes and 18 CLIA highly complex drugs of abuse screening reagents. State-of-the-art features such as an automated daily maintenance processes, intuitive software and an intelligent probe management system enable operational ease of use and confidence in the results.
Drugs of abuse is an important growth category in IVD (in vitro diagnostic) testing with competitive participation by top IVD vendors for market share. Healthcare professionals, employers, criminal justice personnel, and sports leagues use drug tests as part of a comprehensive evaluation of individuals to reach a correct decision regarding individuals' actions, behaviors or performances.
The geographic scope of Drugs of Abuse Testing Markets is worldwide with information for specific geographical regions, world demographics, and other general issues affecting the market. The market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included. The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals.
Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=87714&productid=8284197.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-drugs-of-abuse-testing-advances-at-aacc-2015-300126494.html
SOURCE Kalorama Information